Eyepoint Pharmaceuticals’ (EYPT) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Eyepoint Pharmaceuticals (NASDAQ:EYPT) in a research note issued to investors on Tuesday, MarketBeat.com reports.

Several other research analysts have also issued reports on the company. Guggenheim reaffirmed a “buy” rating and set a $68.00 target price on shares of Eyepoint Pharmaceuticals in a research report on Wednesday, June 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research report on Friday, July 17th. Jefferies Financial Group decreased their price target on Eyepoint Pharmaceuticals to $8.00 and set a “buy” rating for the company in a research note on Monday. Chardan Capital restated a “neutral” rating and set a $5.00 price objective (down from $65.00) on shares of Eyepoint Pharmaceuticals in a research report on Monday. Finally, Stifel Nicolaus assumed coverage on Eyepoint Pharmaceuticals in a research note on Thursday, July 16th. They issued a “buy” rating and a $40.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $28.11.

Eyepoint Pharmaceuticals Stock Performance

Shares of NASDAQ EYPT opened at $5.40 on Tuesday. Eyepoint Pharmaceuticals has a 52-week low of $3.95 and a 52-week high of $19.11. The firm has a 50 day moving average price of $12.71 and a two-hundred day moving average price of $13.44. The stock has a market cap of $465.53 million, a P/E ratio of -1.44 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%.The business had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.45 million. Analysts predict that Eyepoint Pharmaceuticals will post -3.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of EYPT. KBC Group NV acquired a new stake in Eyepoint Pharmaceuticals during the 1st quarter worth about $29,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Eyepoint Pharmaceuticals by 51.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock valued at $74,000 after purchasing an additional 1,358 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of Eyepoint Pharmaceuticals in the 3rd quarter valued at about $76,000. Tower Research Capital LLC TRC boosted its position in shares of Eyepoint Pharmaceuticals by 218.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after purchasing an additional 5,967 shares in the last quarter. Finally, California State Teachers Retirement System boosted its position in shares of Eyepoint Pharmaceuticals by 20.6% during the 4th quarter. California State Teachers Retirement System now owns 4,654 shares of the company’s stock valued at $85,000 after purchasing an additional 794 shares in the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

Key Headlines Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Management has argued that the failed LUGANO Phase 3 trial may have been distorted by an anomalous group of nine patients—about 4% of participants—with vision loss unrelated to wet AMD. The company also highlighted favorable secondary endpoints and Duravyu’s potential durability advantages. Positive results from the upcoming LUCIA Phase 3 trial, expected in the fourth quarter of 2026, could help restore confidence in the program. EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown
• Neutral Sentiment: Unusually heavy options activity indicates elevated trading and hedging interest, but does not establish a clear directional signal for EYPT. Eyepoint Pharmaceuticals Sees Unusually Large Options Volume
• Negative Sentiment: EyePoint is facing a shareholder investigation by SueWallSt over potential securities-law claims. Such notices can add legal uncertainty and further weigh on investor sentiment. EYPT Shareholder Investigation
• Negative Sentiment: Analyst sentiment has deteriorated following the trial result. Chardan Capital lowered its rating to Neutral, while Royal Bank of Canada cut EyePoint to Sector Perform and set a $5 price target. HC Wainwright, Cantor Fitzgerald, and JPMorgan maintained neutral-equivalent ratings, and Jefferies reduced its expectations. The broad lack of bullish ratings limits near-term valuation support. Chardan Capital Rating
• Negative Sentiment: The LUGANO Phase 3 failure caused a sharp sell-off because Duravyu did not meet its primary endpoint against Eylea. Analysts continue to view the result as a substantial risk to EyePoint’s pipeline and valuation, despite management’s explanation and the pending LUCIA data. EyePoint: Still A Sell After Phase 3 Crash

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.